The 2026 U.S. Addiction Policy Landscape

Body: Policy in 2026 is a rare mix of tailwinds and risks. On the tailwinds side: DEA and HHS extended telemedicine flexibilities for controlled substance prescribing through December 31, 2026 — and a final rule now permanently allows buprenorphine prescribing via telehealth for up to six months without an in-person visit. That’s a generational change in how OUD care can be delivered.

SAMHSA’s State Opioid Response (SOR) grants continue to fund states at ~$1.5B annually for prevention, treatment, and recovery. HHS has been receptive to Medicaid IMD exclusion waivers, which allow reimbursement for residential treatment at larger facilities — potentially unlocking capacity.

On the risk side: Proposed Medicaid work requirements and potential ACA rollbacks could reduce SUD coverage for the populations that need it most. Any shift here reshapes the economics of treatment overnight.

And then there’s the money nobody is talking about enough — the opioid settlements. Arizona alone is receiving $1.215 billion over 18 years. Nationally, settlements are approaching $50 billion. How states spend this will define the next decade of infrastructure.

Related reads: DEA extends telemedicine buprenorphine | What SAMHSA SOR grants actually do | The Arizona opioid settlement, explained.